Actinogen logo

Actinogen Medical

AU: ACW

Market CapAU$140m

Last Close AU$0.08

Actinogen Medical is an ASX-listed Australian biotech developing lead asset Xanamem, a brain-penetrant 11beta-HSD1 inhibitor designed to treat cognitive impairment and other symptoms that occur in chronic neurological diseases.

More Actinogen Medical content >

Investment summary

Listed on the ASX and headquartered in Sydney, Australia, Actinogen is a biotechnology company developing its lead product Xanamem, 11beta-HSD1 inhibitor, a novel once-a-day oral cognitive enhancer. The company’s focus at present is cognition impairment in a variety of diseases, with a focus on early-stage Alzheimer’s disease (AD) and Major Depressive Disorder (MDD). The XanaMIA Part A trial (n=107) investigated the ability of Xanamem to enhance cognition in healthy older volunteers, with positive safety and efficacy results recently reported. The Part B Phase II trial will investigate the use of Xanamem in patients with the early stages of AD and should commence later in 2022. The second indication is MDD, which is based on the rationale that elevated cortisol levels have been associated with depression, with a Phase II trial to start later in the year.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2020A 3.6 (5.3) (5.3) (0.474) N/A N/A
2021A 2.0 (3.9) (3.9) (0.277) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

The unmet need in chronic neurological and neuropsychiatric disorders is high due to limited effectiveness of available treatment options. As there are not many options available, there is a notable market opportunity for an effective cognitive enhancing drug in AD and MDD (used alone or in combination with other therapies).

Last updated on 15/09/2022
Content on Actinogen Medical
Actinogen: Edison Open House Healthcare 2022
Healthcare | Edison TV | 8 February 2022
Executive interview – Actinogen Medical
Healthcare | Edison TV | 22 November 2019
Actinogen Medical – Well-timed XanaHES study saves the day
Healthcare | research Update | 15 October 2019
Actinogen logo
View more
Register to receive research on Actinogen Medical as it is published
Share price graph
Balance sheet
Forecast net debt (A$m) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 30.0 9.9 (25.7)
Relative* 24.9 11.4 (20.4)
52-week high/low A$0.2/A$0.0
*% relative to local index
Key management
Dr Steven Gourlay CEO and MD